Stable Istotope Labelled Margetuximab Biosimilar – Anti-ERBB2/EGFR2/CD340 mAb – Research Grade

Reference: PX-TA1331-SIL-1MG
Product nameStable Istotope Labelled Margetuximab Biosimilar - Anti-ERBB2/EGFR2/CD340 mAb - Research Grade
SourceCAS 1350624-75-7
SpeciesChimeric
Expression systemMammalian cells
Purity>95%
BufferPBS buffer PH7.5
Delivery conditionBlue Ice
Delivery Time3-5 days if in stock; 5-8 weeks if production needed
Storage conditionstore at -80°C
BrandProteoGenix
Aliases /SynonymsMGAH-22
ReferencePX-TA1331-SIL
Related ProductsPX-P3061
NoteFor research use only. Not suitable for clinical or therapeutic use.
IsotypeIgG1-kappa
ClonalityMonoclonal Antibody
FormatLyophilized
LabellingArginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99%
Isotopic Enrichment99%
Stability1 year

General information on Anti-ERBB2/EGFR2/CD340[Homo sapiens] (Margetuximab) Monoclonal Antibody

Margetuximab is an Fc-engineered human/mouse chimeric anti-HER2 monoclonal antibody of isotype IgG1? . Margetuximab targets the same epitope on the HER2 extracellular domain and hass the same activity as trastuzumab. However, margetuximab has a higher affinity for both CD16A variants and a weaker one to the inhibitory CD32B Fc receptor, thereby resulting in more efficient antibody-dependent cell-mediated cytotoxicity (ADCC) and higher efficacy compared to trastuzumab. Margetuximab has been marketed under the trade name Margenza.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “Stable Istotope Labelled Margetuximab Biosimilar – Anti-ERBB2/EGFR2/CD340 mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.